Comparison of Microscopic Hematuria Guidelines as Applied in 1018 Patients With Microscopic Hematuria

Area of Science:

• Urology
• Nephrology
• Oncology

Background:

• Microscopic hematuria (MH) evaluation guidelines have evolved.
• Accurate risk stratification is crucial for identifying urinary tract malignancies.
• The 2012 American Urological Association (AUA) guidelines were previously standard for MH management.

Purpose of the Study:

• To compare the diagnostic yield of the 2012 AUA and 2020 AUA/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) microscopic hematuria guidelines.
• To re-evaluate risk groups for urinary tract malignancy using the updated guidelines.
• To investigate the natural history of patients diagnosed with microscopic hematuria.

Main Methods:

• Retrospective analysis of 1,018 patients with microscopic hematuria evaluated under the 2012 AUA guidelines.
• Reclassification of patients into risk groups (low, intermediate, high) based on the 2020 AUA/SUFU guidelines.
• Comparison of diagnostic outcomes and malignancy detection rates between the two guideline sets.

Main Results:

• A total of 1,018 patients with microscopic hematuria were analyzed, with a 3.3% malignancy rate.
• The 2020 AUA/SUFU guidelines classified 21.4% as low-risk, 43.9% as intermediate-risk, and 34.6% as high-risk.
• All 34 malignancies were identified in the intermediate- and high-risk groups; no new malignancies developed during follow-up.

Conclusions:

• The updated 2020 AUA/SUFU microscopic hematuria guidelines can potentially decrease the number of diagnostic procedures.
• Implementation of the 2020 guidelines may achieve this reduction without compromising the detection of serious malignant conditions.
• The updated guidelines offer a more refined approach to risk stratification for patients with microscopic hematuria.